Skip to main content
. 2024 Jan 15;10(1):00612-2023. doi: 10.1183/23120541.00612-2023

TABLE 2.

Univariable Cox analyses

Hazard ratio 95% CI p-value
Sex (male) 1.330 0.939–1.882 0.108
Age, per year 1.032 1.018–1.046 <0.001
Body mass index, per kg·m−2 1.007 0.978–1.036 0.646
Biallelic EIF2AK4 mutations 3.176 1.177–8.570 0.023
NYHA FC, per class 1.697 1.303–2.209 <0.001
6MWD, per m 0.997 0.996–0.998 <0.001
BNP, per ng·L−1 1.000 1.000–1.000 0.053
NT-proBNP, per ng·L−1 1.000 1.000–1.000 0.019
RAP, per mmHg 1.026 0.991–1.062 0.146
mPAP, per mmHg 1.001 0.987–1.015 0.874
PAWP, per mmHg 0.957 0.914–1.001 0.058
Cardiac output, per L·min−1 0.856 0.753–0.973 0.017
Cardiac index, per L·min−1·m−2 0.673 0.524–0.864 0.002
PVR, per WU 1.018 0.985–1.053 0.290
S vO2 , per % 0.970 0.948–0.992 0.007
P aO2 , per mmHg 0.979 0.966–0.993 0.003
P aCO2 , per mmHg 1.012 0.980–1.044 0.472
TLC, per % 0.997 0.988–1.007 0.599
FEV1, per % 0.999 0.991–1.007 0.781
D LCO , per % 0.980 0.967–0.993 0.002
D LCO /AV, per % 0.990 0.980–1.000 0.054
Number of PAH therapies 0.793 0.597–1.053 0.108

EIF2AK4: Eukaryotic translation initiation factor 2-α kinase 4; NYHA FC: New York Heart Association functional class; 6MWD: 6-min walk distance; BNP: brain natriuretic peptide; NT-proBNP: N-terminal pro-brain natriuretic peptide; RAP: right atrial pressure; mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; SvO2: mixed venous oxygen saturation; PaO2: partial pressure of oxygen; PaCO2: partial pressure of carbon dioxide; TLC: total lung capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity for carbon monoxide; DLCO/AV: diffusing capacity for carbon monoxide to alveolar volume ratio; PAH: pulmonary arterial hypertension.